Services to deliver Onasemnogene abeparvovec/Zolgensma
Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabl...
Buyer
NHS Arden and Greater East Midlands Commissioning Support Unit
Value
£6,000,000
Published
30 Jun 2021
Closes
8 Mar 2021
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Open
Category
Services
Contract starts
30 May 2021
Contract ends
30 May 2026
CPV classifications
85000000
Health and social work services
Lots
Lot default Services to deliver Onasemnogene abeparvovec/Zolgensma
£6,000,000
Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival...
Delivery: British Oversea Territories, Channel Islands, Europe, Isle of Man, Rest of the World, United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
30 Jun 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
Additional data
Not provided
Additional data
Link
User / Company
Not provided
User / Company
Link
Contains public sector information licensed under the Open Government Licence v3.0.